<DOC>
	<DOCNO>NCT02426411</DOCNO>
	<brief_summary>The study randomize , double blind , placebo-controlled , parallel-group comparison ( two dose level EMA401 versus placebo group ) , safety efficacy patient postherpetic neuralgia .</brief_summary>
	<brief_title>Dose Ranging Trial Determine Safety Efficacy EMA401 Patients With PHN</brief_title>
	<detailed_description>Screening Period ( Up Four Weeks ) confirm eligibility study determine Screening test , physical examination/medical history fulfillment eligibility criterion include assessment pain . Study Period ( 14 Weeks ) Approximately 360 eligible male female patient receive double-blind treatment 14 week . Patients randomize 1:1:1 ratio treatment EMA401 100 mg BID , 300 mg BID placebo . Patients attend study site end Baseline visit end Weeks 1 , 3 , 5 , 7 , 9 , 11 , 13 , 14 on-study assessment .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Be diagnose suffer PHN define pain region rash persist six month onset herpes zoster rash . Be assess suffer moderate severe pain across Screening Period . The assessment moderate severe pain make use algorithm proprietary Spinifex . The Investigator/site staff inform immediately whether patient eligible ineligible ePRO website base patient enter relevant pain score eDiary device . Women child bear potential ( WOCBP ) must negative urine pregnancy test Screening Visit ( Visit 1 ) within 72 hour prior administration IP . Patients take topical treatment PHN time Screening Visit 2 exclude , include lidocaine plaster , capsaicin patch , topical preparation topical medication ( e.g. , aspirin , NonSteroidal AntiInflammatory Drugs ( NSAIDs ) ) PHN . Have blood pressure reading , rest least five minute , outside systolic blood pressure range 84151 mmHg diastolic blood pressure &gt; 95 mmHg . If blood pressure outside range , repeat measurement take patient rest . The repeat measurement use screen value . Have serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) level &gt; 1.5 x upper limit normal total bilirubin concentration &gt; 1.5 x upper limit normal Screening ( Visit 1 ) . Patients know diagnosis diabetes stable medication hemoglobin A1c &gt; 8 % . Those know diagnosis diabetes hemoglobin A1c &gt; 7 % . Have active herpes zoster upon physical examination Screening ( Visit 1 ) study . Known history , positive laboratory result hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection define seropositive hepatitis B surface antigen ( HBsAg ) , HCV antibodies HIV antibody respectively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>